Products
Mebucaïne f lozenges were approved in many countries in 1983 (Wander, Sandoz, Novartis, GSK). During 2018, they were replaced by Mebucaïne N lozenges with a new composition. The new drug contains the antiseptic cetylpyridinium chloride and the local anesthetic lidocaine, without the antibiotic thyrotricin. The addition of the antibiotic has been controversial for years because it is insufficiently effective for streptococcal angina. In addition, sore throats are often viral infections for which antibiotics are not suitable therapy. The following information refers to the old formulation (Mebucaïne f).
Ingredients
The lozenges contained the following active ingredients:
- Tyrothricin (antibiotic).
- Cetylpyridinium chloride (disinfectant).
- Oxybuprocaine (local anesthetic)
Menthol was added as an aromatic.
Effects
Mebucaïne f had antibacterial (bacteriostatic to bactericidal), antiseptic and local anesthetic (analgesic, local anesthetic) properties.
Indications
- Inflammation, infection, or pain of the oral and pharyngeal mucosa, including the gums
- Difficulty swallowing
- Hoarseness
- Pharyngitis, additional medication for angina.
- Inflammation of the gums after oral surgery or dental surgery, aphthae, stomatitis.
Dosage
According to the professional information. Adults: dissolve one lozenge in the mouth every two to three hours, in severe infections every hour to every second. Maximum dosage: 12 tablets daily.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
The antibacterial activity of cetylpyridinium chloride is reduced by anionic surfactants (eg, toothpaste) used at the same time.
Adverse effects
Possible adverse effects include hypersensitivity reactions. Application of tyrothricin to fresh wounds may cause bleeding.
